Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors.

Michael F GowenKeith M GilesDanny SimpsonJeremy TchackHua ZhouUna MoranZarmeena DawoodAnna C PavlickShaohui HuMelissa A WilsonHua ZhongMichelle KrogsgaardTomas KirchhoffIman Osman

Published in: Journal of translational medicine (2018)

Our results provide the first evidence supporting a predisposition to develop severe irAEs upon immune system disinhibition, which requires further independent validation in a clinical trial setting.

Keyphrases

clinical trial
early onset
oxidative stress
phase ii
open label
double blind
study protocol
skin cancer
phase iii